Results 131 to 140 of about 82,604 (202)

Anticancer Quinolinol Small Molecules Target Multiple Pathways to Promote Cell Death and Eliminate Melanoma Cells Resistant to BRAF Inhibitors. [PDF]

Molecules
Wang X, Lama R, Kelleher AD, Rizzo EC, Galster SL, Xue C, Zhang Y, Wang J, Qu J, Chemler SR.   +9 more
europepmc   +1 more source

Combination Atezolizumab, Cobimetinib, and Vemurafenib as a Treatment Option in BRAF V600 Mutation–Positive Melanoma: Patient Selection and Perspectives

Cancer Management and Research
Michelle M Dugan,1 Matthew C Perez,1 Lilit Karapetyan,1,2 Jonathan S Zager1,2 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA; 2Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL,
Dugan MM, Perez MC, Karapetyan L, Zager JS   +3 more
doaj  

Update on Neoadjuvant and Adjuvant BRAF Inhibitors in Papillary Craniopharyngioma: A Systematic Review. [PDF]

Cancers (Basel)
Cossu G, Ramsay DSC, Daniel RT, El Cadhi A, Kerherve L, Morlaix E, Houidi SA, Millot-Piccoli C, Chapon R, Le Van T, Cao C, Farah W, Lleu M, Baland O, Beaurain J, Petit JM, Lemogne B, Messerer M, Berhouma M.   +18 more
europepmc   +1 more source

BRAF inhibitors enhance erythropoiesis and treat anemia through paradoxical activation of MAPK signaling. [PDF]

Signal Transduct Target Ther
Wu S, Deng Y, Sun H, Liu X, Zhou S, Zhao H, Li H, Guo F, Yue Q, Wu F, Zhao X, Li N, Zhu S, Hu Q, Xie S, Zheng J, Lv M, Kong Y, Huang XJ, Lei X, Tong X, Gao X, Lee HY.   +22 more
europepmc   +1 more source

Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma. [PDF]

Neurooncol Adv
Ayanlaja AA, Chang M, Lalwani K, Ioannou M, Wang J, Jagtap S, Yang Y, Lucas CG, Mulcahy-Levy JM, Gartrell RD, Pratilas CA, Schreck KC.   +11 more
europepmc   +1 more source

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function. [PDF]

Life Sci Alliance
Bromberger S, Zadorozhna Y, Ressler JM, Holzner S, Nawrocki A, Zila N, Springer A, Røssel Larsen M, Schossleitner K.   +8 more
europepmc   +1 more source

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells. [PDF]

Int J Mol Sci, 2021
Bonaldi E, Gargiuli C, De Cecco L, Micali A, Rizzetti MG, Greco A, Borrello MG, Minna E.   +7 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK Inhibitors

JACC: CardioOncology, 2023
Claire Glen, Sarah Adam, Kirsty McDowell, Ashita Waterston, Yun Yi Tan, Mark C. Petrie, Caroline J. Coats, Ninian N. Lang   +7 more
openaire   +1 more source

Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors. [PDF]

Cell Mol Life Sci
Sui F, Wang G, Liu J, Yuan M, Chen P, Yao Y, Zhang S, Ji M, Hou P.   +8 more
europepmc   +1 more source

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.

Blood, 2022
Falini B, De Carolis L, Tiacci E.
europepmc   +1 more source